Clinical Trial Update: A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate how the investigational cancer drug BI 764532 is taken up by tumors in people with small cell lung cancer or neuroendocrine neoplasms;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors
• Small Cell Lung Cancer

Drugs mentioned

• BI 764532 (BI 764532)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Small Cell Lung Carcinoma (SCLC), Neuroendocrine Neoplasms | Phase 1 | Status: RECRUITING